# Aldosterone and the Metabolic Syndrome

> **NCT01103245** · PHASE1 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 69 (actual)

## Conditions studied

- Metabolic Diseases
- Diabetes Mellitus
- Endocrine System Diseases
- Glucose Metabolism Disorders

## Interventions

- **DRUG:** Hydrochlorothiazide (HCTZ)
- **DRUG:** Aliskiren 150 mg (ALI 150)
- **DRUG:** Spironolactone (SPL 25)
- **DRUG:** Aliskiren 300 mg (ALI 300)
- **DRUG:** Spironolactone 50 mg (SPL 50)

## Key facts

- **NCT ID:** NCT01103245
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-07
- **Final completion:** 2013-09
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01103245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01103245, "Aldosterone and the Metabolic Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01103245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*